Which of the following is a first-line disease-modifying therapy for relapsing multiple sclerosis?

Prepare for the PANCE Neurology Test with comprehensive materials. Use flashcards and multiple-choice questions, each featuring hints and explanations. Boost your confidence and ace your exam!

Multiple Choice

Which of the following is a first-line disease-modifying therapy for relapsing multiple sclerosis?

Interferon beta is a classic first-line disease-modifying therapy for relapsing multiple sclerosis because it has a long track record of reducing relapse rate and MRI activity while maintaining a favorable safety profile. In numerous trials, it lowers the annualized relapse rate by about a third and decreases new lesions on MRI, with manageable side effects such as flu-like symptoms and injection-site reactions. This combination of solid efficacy data and tolerability makes it a typical starting option early in the disease course. Other therapies can be used early as well, but they come with different risk–benefit considerations. Glatiramer acetate offers a similar level of safety and efficacy and is also used upfront. Ocrelizumab tends to be viewed as a higher-efficacy option with greater infection risk and monitoring needs, often reserved for patients who need stronger suppression of disease activity. Fingolimod is effective but carries safety concerns like cardiovascular effects and infection risk, which can push it toward later in the treatment sequence depending on the clinical scenario.

Interferon beta is a classic first-line disease-modifying therapy for relapsing multiple sclerosis because it has a long track record of reducing relapse rate and MRI activity while maintaining a favorable safety profile. In numerous trials, it lowers the annualized relapse rate by about a third and decreases new lesions on MRI, with manageable side effects such as flu-like symptoms and injection-site reactions. This combination of solid efficacy data and tolerability makes it a typical starting option early in the disease course.

Other therapies can be used early as well, but they come with different risk–benefit considerations. Glatiramer acetate offers a similar level of safety and efficacy and is also used upfront. Ocrelizumab tends to be viewed as a higher-efficacy option with greater infection risk and monitoring needs, often reserved for patients who need stronger suppression of disease activity. Fingolimod is effective but carries safety concerns like cardiovascular effects and infection risk, which can push it toward later in the treatment sequence depending on the clinical scenario.

More practice questions